Cellular and cytokine-dependent immunosuppressive mechanisms of grm1-transgenic murine melanoma

Cancer Immunology, Immunotherapy

Volumn 61, Issue 12, 2012, Pages 2239-2249

  Alb, Miriam ^a   Sie, Christopher ^a,b   Adam, Christian ^a   Chen, Suzie ^c   Becker, Jürgen C ^d   Schrama, David ^d  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c RUTGERS UNIVERSITY   (United States)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Immune suppression; Melanoma; Regulatory T cell; Tumor draining lymph node

Indexed keywords

CYTOKINE; INTERLEUKIN 10; METABOTROPIC RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNODEFICIENCY; CONTROLLED STUDY; CUTANEOUS MELANOMA; CYTOKINE DEPENDENT IMMUNE DEFICIENCY; EX VIVO STUDY; HELPER CELL; IMMUNE DEFICIENCY; IMMUNOMODULATION; IN VITRO STUDY; LYMPH NODE; LYMPHOCYTE; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOID ORGAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; TUMOR ESCAPE; TUMOR VOLUME;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; LYMPH NODES; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOGENS; RECEPTORS, METABOTROPIC GLUTAMATE; RNA, MESSENGER; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84871003934     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1290-9     Document Type: Article

References (45)

1. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329-360. doi:10.1146/ annurev.immunol.22. 012703.104803
2. Ramirez-Montagut T, Turk MJ, Wolchok JD, Guevara-Patino JA, Houghton AN (2003) Immunity to melanoma: Unraveling the relation of tumor immunity and autoimmunity. Oncogene 22:3180-3187. doi:10.1038/sj.onc.1206462
3. Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P (2001) Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 61:5964-5968
4. Zhang L, Conejo-Garcia JR, Katsaros D et al (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203-213. doi:10.1056/NEJMoa020177
5. van Houdt IS, Sluijter BJ, Moesbergen LM et al (2008) Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int J Cancer 123:609-615. doi:10.1002/ijc.23543
6. Rosenberg SA, Sherry RM, Morton KE et al (2005) Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8? T cells in patients with melanoma. J Immunol 175:6169-6176
7. Becker JC, Brabletz T, Czerny C, Termeer C, Brocker EB (1993) Tumor escape mechanisms from immunosurveillance: Induction of unresponsiveness in a specific MHC-restricted CD4? human T cell clone by the autologous MHC class II? melanoma. Int Immunol 5:1501-1508. doi:10.1093/intimm/5.12.1501
8. Fujiwara K, Higashi T, Nouso K et al (2004) Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma. J Gastroenterol Hepatol 19:1121-1127. doi:10.1111/j.1440-1746. 2004.03467.x
9. Mizukami Y, Kono K, Maruyama T et al (2008) Downregulation of HLA class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma. Br J Cancer 99:1462-1467. doi:10.1038/sj.bjc.6604715
10. Yue FY, Dummer R, Geertsen R et al (1997) Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 71:630-637. doi:10.1002/(SICI)1097- 0215(19970516)71:4\630: AID-IJC20[3.0.CO;2-E
11. Yan Z, Kim GY, Deng X, Friedman E (2002) Transforming growth factor beta 1 induces proliferation in colon carcinoma cells by Ras-dependent, smad-independent down-regulation of p21cip1. J Biol Chem 277:9870-9879. doi:10.1074/jbc.M1076 46200
12. Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB (1995) Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 5:67-68
13. Krasagakis K, Tholke D, Farthmann B, Eberle J, Mansmann U, Orfanos CE (1998) Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br J Cancer 77:1492-1494
14. Ivanovic V, Demajo M, Krtolica K et al (2006) Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients. Clin Chim Acta 371:191-193. doi: 10.1016/j.cca.2006.02.027
15. Seo N, Hayakawa S, Takigawa M, Tokura Y (2001) Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(?) T-regulatory cells and systemic collapse of antitumour immunity. Immunology 103:449-457. doi:10.1046/j.1365-2567.2001.01279.x
16. Chen ML, Pittet MJ, Gorelik L et al (2005) Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGFbeta signals in vivo. Proc Natl Acad Sci U S A 102:419-424. doi: 10.1073/pnas.0408197102
17. Liu VC, Wong LY, Jang T et al (2007) Tumor evasion of the immune system by converting CD4? CD25-T cells into CD4? CD25? T regulatory cells: Role of tumor-derived TGF-beta. J Immunol 178:2883-2892
18. Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH (1999) Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(?) T cells resulting in a failure to lyse tumor cells. Blood 93:1634-1642
19. Gorelik L, Flavell RA (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7:1118-1122. doi:10.1038/ nm1001-1118
20. Wilke CM, Wu K, Zhao E, Wang G, Zou W (2010) Prognostic significance of regulatory T cells in tumor. Int J Cancer 127: 748-758. doi:10.1002/ijc.25464
21. Colon-Teicher L, Wise LS, Martino JJ et al (1993) Genomic sequences capable of committing mouse and rat fibroblasts to adipogenesis. Nucleic Acids Res 21:2223-2228. doi:10.1093/nar/ 21.9.2223
22. Chen S, Zhu H, Wetzel WJ, Philbert MA (1996) Spontaneous melanocytosis in transgenic mice. J Invest Dermatol 106:1145-1151. doi:10.1111/1523-1747. ep12340194
23. Pollock PM, Cohen-Solal K, Sood R et al (2003) Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet 34:108-112. doi:10.1038/ ng1148
24. Cohen-Solal KA, Reuhl KR, Ryan KB, Roberts KG, Chen S (2001) Development of cutaneous amelanotic melanoma in the absence of a functional tyrosinase. Pigment Cell Res 14:466-474. doi:10.1034/j.1600-0749.2001.140607.x
25. Ziegler SF, Ramsdell F, Alderson MR (1994) The activation antigen CD69. Stem Cells 12:456-465. doi:10.1002/stem. 5530120502
26. Lowenthal JW, Zubler RH, Nabholz M, MacDonald HR (1985) Similarities between interleukin-2 receptor number and affinity on activated B and T lymphocytes. Nature 315:669-672. doi: 10.1038/315669a0
27. Nishikawa H, Sakaguchi S (2010) Regulatory T cells in tumor immunity. Int J Cancer 127:759-767. doi:10.1002/ijc.25429
28. Chin L, Garraway LA, Fisher DE (2006) Malignant melanoma: Genetics and therapeutics in the genomic era. Genes Dev 20:2149-2182. doi:10.1101/gad.1437206
29. de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6:24-37. doi:10.1038/nrc1782
30. Whiteside TL (2010) Immune responses to malignancies. J Allergy Clin Immunol 125:S272-S283. doi:10.1016/j.jaci. 2009.09.045
31. Hoon DS, Korn EL, Cochran AJ (1987) Variations in functional immunocompetence of individual tumor-draining lymph nodes in humans. Cancer Res 47:1740-1744
32. Elliott LH, Brooks WH, Roszman TL (1990) Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors. J Clin Invest 86:80-86. doi:10.1172/JCI114719
33. Russ AJ, Xu K, Wentworth L et al (2011) Melanoma-induced suppression of tumor antigen-specific T cell expansion is comparable to suppression of global T cell expansion. Cell Immunol 271:104-109. doi:10.1016/j.cellimm.2011.06.011
34. Woo EY, Yeh H, Chu CS et al (2002) Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168:4272-4276
35. Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell 133:775-787. doi: 10.1016/j.cell.2008.05.009
36. Rausch MP, Hastings KT (2011) GILT modulates CD4(?) T-cell tolerance to the melanocyte differentiation antigen tyrosinaserelated protein 1. J Invest Dermatol. doi:10.1038/jid.2011.236
37. Viguier M, Lemaitre F, Verola O et al (2004) Foxp3 expressing CD4? CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173:1444-1453
38. Polak ME, Borthwick NJ, Gabriel FG et al (2007) Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer 96:1879-1887. doi:10.1038/sj.bjc.6603763
39. Matsuda M, Salazar F, Petersson M et al (1994) Interleukin 10 pretreatment protects target cells from tumor-and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 180:2371-2376. doi:10.1084/jem.180.6.2371
40. Ito M, Minamiya Y, Kawai H et al (2006) Tumor-derived TGFbeta-1 induces dendritic cell apoptosis in the sentinel lymph node. J Immunol 176:5637-5643
41. Thomas DA, Massague J (2005) TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8:369-380. doi:10.1016/j.ccr.2005.10.012
42. Jarnicki AG, Lysaght J, Todryk S, Mills KH (2006) Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: Influence of tumor environment on the induction of CD4? and CD8? regulatory T cells. J Immunol 177:896-904
43. Willems F, Marchant A, Delville JP et al (1994) Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol 24:1007-1009. doi:10.1002/ eji.1830240435
44. Umansky V, Sevko A (2012) Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation. Cancer Immunol Immunother 61:275-282. doi:10.1007/ s00262-011-1164-6
45. Endharti AT, Rifa'I M, Shi Z et al (2005) Cutting edge: CD8? CD122? regulatory T cells produce IL-10 to suppress IFNgamma production and proliferation of CD8? T cells. J Immunol 175:7093-7097